Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4706167 | 0.91 | KDM1A (0.51) | MMP8KDM1AF10MEN1KMT2A | |
| SCHEMBL4706069 | 0.88 | KDM1A (0.42) | MMP8KDM1AF10TSHRF2 | |
| SCHEMBL4704111 | 0.83 | ALDH1A1 (0.42) | MMP8KDM1AF10ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4757424 | 0.82 | NPC1 (0.44) | MMP8KDM1AMEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4757426 | 0.82 | NPC1 (0.44) | MMP8KDM1AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4705662 | 0.81 | F10 (0.40) | MMP8KDM1AF10F2KLKB1 | |
| SCHEMBL4705534 | 0.81 | F10 (0.43) | F10SMN1; SMN2ALDH1A1F2KLKB1 | |
| SCHEMBL4702122 | 0.81 | F10 (0.41) | F10F2KLKB1ELANEPOLB | |
| SCHEMBL4706596 | 0.79 | F10 (0.39) | F10F2KLKB1ELANEPOLB | |
| SCHEMBL4706056 | 0.79 | F10 (0.39) | F10F2KLKB1ELANEPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567489-B1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | GLAXO GROUP LIMITED (GB) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | TFPI, TFPI2, SERPINC1 | MMP8 141/4885KDM1A 2422/4885F10 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.